Cargando…

Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union

The Committee for Orphan Medicinal Products (COMP) evaluates prevalence of rare conditions as one of the criteria for granting an orphan designation with a prevalence threshold of 5 in 10.000. At the time of Marketing Authorisation (MA) these criteria are reassessed to ensure they are still met. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polsinelli, Benedetta, Tsigkos, Stelios, Naumann-Winter, Frauke, Mariz, Segundo, Sepodes, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5251220/ https://www.ncbi.nlm.nih.gov/pubmed/28109318 http://dx.doi.org/10.1186/s13023-017-0567-7

Ejemplares similares

Establishing medical plausibility in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014)

Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2015)

Use of biomarkers in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014)

Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021)

Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008)

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective
por: Sheean, Maria E., et al.
Publicado: (2021)

Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021)

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review
por: Anker, Markus S., et al.
Publicado: (2019)

Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe
por: Farkas, Andreas M., et al.
Publicado: (2017)

A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020
por: Teixeira, Maria Manuel, et al.
Publicado: (2022)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
por: Balkhi, Bander, et al.
Publicado: (2023)

Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021
por: Naumann-Winter, Frauke, et al.
Publicado: (2022)

Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union
por: Żelewski, Paweł, et al.
Publicado: (2022)

Survival of critically ill patients with haematological malignancies compared with patients without haematological malignancy
por: Pugh, R, et al.
Publicado: (2013)

PSYCHOLOGICAL ASPECTS OF HAEMATOLOGICAL MALIGNANCIES
por: Kulhara, P., et al.
Publicado: (1990)

Tuberculosis in Patients with Haematological Malignancies
por: Anibarro, Luis, et al.
Publicado: (2014)

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
por: Smith, A, et al.
Publicado: (2011)

PB1714: DEXRAZOXANE IN HAEMATOLOGICAL PATIENTS: A META-ANALYSIS OF THE CARDIOPROTECTIVE EFFICACY, RISK OF SECONDARY MALIGNANCIES AND IMPACT IN SURVIVAL OUTCOMES
por: Pimenta, Mario Sousa, et al.
Publicado: (2023)

The European Health Union and the protection of public health in the European Union: Is the European Union prepared for future cross-border health threats?
por: Seitz, Claudia
Publicado: (2023)

The Evolving Role of Haematology Nursing Practice: A Cross-Sectional Survey
por: Liptrott, Sarah, et al.
Publicado: (2023)

The European Union and the Regions /
Publicado: (1995)

The European challenges of funding orphan medicinal products
por: Szegedi, Márta, et al.
Publicado: (2018)

Expression of testicular genes in haematological malignancies
por: Lim, S H, et al.
Publicado: (1999)

Clinical use of rituximab in haematological malignancies
por: Avivi, I, et al.
Publicado: (2003)

The Role of miRNA in Haematological Malignancy
por: Gounaris-Shannon, Stephanie, et al.
Publicado: (2013)

Cancer stem cells in haematological malignancies
por: Zagozdzon, Radoslaw, et al.
Publicado: (2015)

Breast imaging findings in haematological malignancies
por: Glazebrook, K. N., et al.
Publicado: (2014)

The hypoxia signalling pathway in haematological malignancies
por: Irigoyen, Marta, et al.
Publicado: (2017)

The Application of CAR-T Cells in Haematological Malignancies
por: Skorka, Katarzyna, et al.
Publicado: (2020)

Clinical Proteomics of Biofluids in Haematological Malignancies
por: Dunphy, Katie, et al.
Publicado: (2021)

COVID-19 in children with haematological malignancies
por: Millen, Gerard Cathal, et al.
Publicado: (2022)

Targeting hypoxia in solid and haematological malignancies
por: Harris, Bill, et al.
Publicado: (2022)

Immune-epigenetic crosstalk in haematological malignancies
por: Wong, Hera, et al.
Publicado: (2023)

Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?
por: Dooms, Marc M
Publicado: (2016)

Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework
por: Carvalho, Marta, et al.
Publicado: (2017)

Preferred and actual place of death in haematological malignancies: a report from the UK haematological malignancy research network
por: Sheridan, Rebecca, et al.
Publicado: (2021)

Selection of Orphan Rhs Toxin Expression in Evolved Salmonella enterica Serovar Typhimurium
por: Koskiniemi, Sanna, et al.
Publicado: (2014)

An evolving perspective on the Pseudomonas aeruginosa orphan quorum sensing regulator QscR
por: Chugani, Sudha, et al.
Publicado: (2014)

The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies – a European survey
por: Lebret, T., et al.
Publicado: (2016)

A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines
por: Garsen, Marjolein, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lpnlpqgknlc0e83j7hbkrmbuki